Search the MBS

Standard Search

Advanced Search Search Tips

Enter keywords or item numbers below
Search Options

Results 1 to 1 of 1 matches



73341 - Additional Information

Item Start Date:
Description Updated:
Schedule Fee Updated:

P7 - Genetics

Fluorescence in situ hybridisation (FISH) test of tumour tissue from a patient with locally advanced or metastatic non-small cell lung cancer, which is of non-squamous histology or histology not otherwise specified, with documented evidence of anaplastic lymphoma kinase (ALK) immunoreactivity by immunohistochemical (IHC) examination giving a staining intensity score > 0, and with documented absence of activating mutations of the epidermal growth factor receptor (EGFR) gene, requested by a specialist or consultant physician, to determine:

  1. if requirements relating to ALK gene rearrangement status for access to an anaplastic lymphoma kinase inhibitor under the Pharmaceutical Benefits Scheme are fulfilled; or
  2. if requirements relating to ALK status for access to pembrolizumab under the Pharmaceutical Benefits Scheme are fulfilled.

Fee: $400.00 Benefit: 75% = $300.00 85% = $340.00

Results 1 to 1 of 1 matches


  • Assist - Addition/Deletion of (Assist.)
  • Amend - Amended Description
  • Anaes - Anaesthetic Values Amended
  • Emsn - EMSN Change
  • Fee - Fee Amended
  • Renum - Item Number Change (renumbered)
  • New - New Item
  • NewMin - New Item (previous Ministerial Determination)
  • Qfe - QFE Change